Analysis of RANK/RANKL expression in metastatic and non-metastatic breast cancer: Systematic literature review
DOI:
https://doi.org/10.33448/rsd-v14i3.48399Keywords:
RANK Ligand, RANK Protein, Neoplasm Metastases, Breast Cancer, Prognosis, Survival.Abstract
Breast cancer is the most frequent cause of death from cancer in the female population worldwide and the clinical management of these patients represents a challenge, given the variety of disease progression profiles. The presence of distant metastasis has a major impact on patient survival, with bone metastases being the most common. The RANK/RANKL/OPG system is identified as a signaling pathway involved in the maintenance of bone homeostasis and mammary gland development. The investigation of the association between the biomarkers expression of receptor activator of nuclear factor kappa B (RANK) and binding protein (RANKL) in the prognostic and predictive assessment of breast cancer helps in the discussion of the use of denosumab in the prevention of bone metastases and in the treatment of the disease. This study aims to present a systematic review on the analysis of RANK/RANKL expression in metastatic and non-metastatic breast cancer. Eight studies totaling 1876 patients were included, and six of the studies demonstrated associations between the occurrence of more aggressive tumors, the metastatic potential of breast cancer, the emergence of bone metastases and, mainly, a worse prognosis in survival curves. The studies included in this review confirm the predictive and prognostic importance of RANK in the evaluation of patients with breast cancer, reaffirming the need for more homogeneous studies for the adequate use of therapeutic and preventive protocols that use this marker as a therapeutic target.
Downloads
References
Abreu, C., et al. (2022). Exploring new pathways in endocrine-resistant breast cancer. Exploration of Targeted Anti-tumor Therapy, 3, 337–361.
Azim, H. A., et al. (2015). RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy. Breast Cancer Research, 17(1).
Buitrago, F., et al. (2011). Fatores prognósticos em câncer de mama. Comunicação em Ciências da Saúde, 69–81.
Hortobagyi, G. N., et al. (2017). AJCC cancer staging manual. Springer International Publishing.
Ibrahim, T., et al. (2011). Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. Clinical Breast Cancer, 11(6), 369–375.
Infante, M., et al. (2019). RANKL/RANK/OPG system beyond bone remodeling: Involvement in breast cancer and clinical perspectives. Journal of Experimental and Clinical Cancer Research, 28.
Instituto Nacional de Câncer José Alencar Gomes da Silva. (2023). Estimativa 2023: incidência de câncer no Brasil. INCA.
International Agency for Research on Cancer. (2020). Cancer today. WHO.
Kiesel, L., & Kohl, A. (2016). Role of the RANK/RANKL pathway in breast cancer. Maturitas, 86, 10–16.
Li, R., et al. (2015). The RANK pathway in advanced breast cancer: Does Src play a role? Disponível em: http://www.r-project.org.
Mamédio, C., et al. (n.d.). The PICO strategy for the research question construction and evidence search. Revista Latino-Americana de Enfermagem. Disponível em: www.eerp.usp.br/rlae. Acessado em 7 de junho de 2023.
Page, M. et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PMJ. 372 (71). doi: https://doi.org/10.1136/bmj.n71.Park, H. S., et al. (2014). Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer. Journal of Surgical Oncology, 807–812.
Pereira A. S. et al. (2018). Metodologia da pesquisa científica. [free e-book]. Editora UAB/NTE/UFSM.
Pfitzner, B. M., et al. (2014). RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Research and Treatment, 145(2), 307–315.
Rang, H. P., et al. (2016). Rang & Dale: Farmacologia (8ª ed.). Editora Elsevier.
Santini, D., et al. (2011). Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One, 6(4).
Santos, C. M. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Rev. Latino-Am. Enfermagem 15 (3). https://doi.org/10.1590/S0104-11692007000300023.
Silva, I., & Branco, J. C. (2011). Rank/Rankl/Opg: literature review. Acta Reumatológica Portuguesa, 36(3), 209–218.
Zhang, L., et al. (2012). Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis. Journal of Clinical Pathology, 65(1), 36–40.
Zhang, L., et al. (2015). The E3 ubiquitin ligase Cbl-b improves the prognosis of RANK positive breast cancer patients by inhibiting RANKL-induced cell migration and metastasis. Oncotarget, 6(26), 22918–22933.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Nathália Machado Terra; Larissa Mota Ramos; Eduardo Chaves Ferreira Coelho; Renot Alves Irineu Neto; Guilherme Fontes de Sousa Skaf Abdala; Isadora Garcia de Paula; Vera Aparecida Saddi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
